Navigation Links
Novel technique uses RNA interference to block inflammation
Date:10/9/2011

Massachusetts General Hospital (MGH) researchers along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication in Nature Biotechnology, the investigators describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage.

"The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, MD, PhD, of the MGH Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such heart disease and cancer."

Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.

Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. Because the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location, the MGH team collaborated with Alnylam scientists who are experts in RNA-interference-based therapeutics and with MIT investigators Robert Langer, ScD, and Daniel Anderson, PhD, who have developed a nanoparticle-based system for delivering mole
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
2. Novel drug combination offers therapeutic promise for hard-to-treat cancers
3. Novel approach scores first success against elusive cancer gene
4. Novel method for increasing antibiotic yields
5. Tropical coral could be used to create novel sunscreens for human use, say scientists
6. A novel mechanism that regulates pro-inflammatory cells is identified
7. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
8. Novel gene increases yeasts appetite for plant sugars
9. Life scientists use novel technique to produce genetic map for African Americans
10. Parkinsons Disease Foundation announces $1 million for novel studies into Parkinsons
11. UTHealth awarded FEMA grant to explore novel obesity risk factor among firefighters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... 2008. A scientific project funded by the BBVA Foundation and ... Research (CSIC) explored around 100 kilometers of practically uncharted Atlantic ... between the years 2006 and 2007. In the course of ... new hope for the survival of the leatherback turtle. This ...
... an animal model of multiple sclerosis (MS), neuroradiologists and ... have been able to visualize inflammatory tissue damage, most ... the aid of a new contrast medium, Gadofluorine M, ... results in the online edition of the renowned medical ...
... the United States die every year from uncontrolled infections ... are pushing the boundaries of molecular science to find ... simple measure of an immune system protein within 24 ... shock can predict survival in children, yielding a powerful ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 30, 2015  With over 60,000 customers across the globe, ISN improves the efficiency ... organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide ... Headquartered in Dallas, TX , ISN ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... SCAI and Endovascular Forum Launch Interactive, Case-Based Website ... VEGAS, May 6 Whether it,s a common ... has likely seen a similar patient. That,s why ... and The Endovascular Forum, Inc. (EVF), an IC ...
... Fabre Dermatologie,specialised department of Pierre Fabre Laboratories, is ... clinical trials following the signature of an exclusive,and ... the University of,Bordeaux. The contract covers the development, ... treatment of severe infantile haemangioma,with the intention of ...
... Provides Simple, Reliable, Easy-to-Use and Affordable Automation for ... European Headquarters and Operations- -See CSampler at the ... American Society of Microbiology 109th Annual Meeting-ANN ARBOR, ... announced the commercial launch of CSampler(TM), an optional ...
Cached Biology Technology:New Website Connects Physicians to Solve Challenging Cases and Share Experiences 2New Website Connects Physicians to Solve Challenging Cases and Share Experiences 3New Website Connects Physicians to Solve Challenging Cases and Share Experiences 4Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma 2Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM) 2Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM) 3Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM) 4
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
...
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: